Relay Therapeutics to present at three investor conferences in November 2026

Relay Therapeutics, a clinical-stage precision medicine company, announced it will participate in three investor fireside chats in November 2026: Guggenheim Healthcare Innovation Conference on Nov 10, UBS Global Biopharma Conference on Nov 17, and Jefferies Global Healthcare Conference on Nov 18. These events will be webcast live and accessible via the company's website, with replays available for 30 days. Relay Therapeutics is advancing its lead drug candidate, zovegalisib, currently in Phase 3 trials for metastatic breast cancer and other genetic diseases, highlighting ongoing progress in its pipeline.

Relay Therapeutics shares trade at USD 17.37 on Pluang as of Nov 03, 2026 04:11 WIB, down 5.34% in the past day. The company’s market cap stands at $4.02 billion with a 52-week high of $20.75. This trading context frames Relay’s upcoming participation in three investor conferences in November, highlighting investor interest amid ongoing clinical developments.